KEEPsAKE 2 results: RZB showed greater improvements in signs & symptoms of PsA vs PBO, met all primary/secondary endpoints, & was well tolerated in Bio-IR or csDMARD-IR pts. Safety profile consistent w/ PsO trials. Abstract #OP0228 #EULAR2021 @RheumNow https://t.co/jsF2JVTupg https://t.co/oiZWZ7Pkf2

• https://ard.bmj.com/content/80/Suppl_1/138

GRAPPA 2021 treatment update highlights! ▶️Domain-specific tx choices ▶️Uveitis & IBD added ▶️ IL17i, IL23i, & JAKi strongly recommended in multiple domains ▶️PDE4i recs for dactylitis, enthesitis, & nail PsO ▶️Against IL6i #OP0229 #EULAR2021 @RheumNow https://t.co/5KFQu7myPO https://t.co/R9YSZBwFDh

• https://ard.bmj.com/content/80/Suppl_1/139#T1

COSMOS study results: GUS 100 mg Q8W showed ⬆️ACR20 vs PBO at W24; results of prespecified sensitivity and subgroup analyses were consistent. Safety profile consistent with PsO & biologic-naïve PsA pts. Abstract #OP0230 #EULAR2021 @RheumNow https://t.co/CFN1MHB9yv https://t.co/BOZqyqaHPe

• http://ow.ly/8qXF50F2ObG

The Association of Psoriatic Arthritis abstract #OP0219 showed no clinically relevant ^ in mortality rate observed in PsA patients between 2003-2018. Mortality trends were similar to those in the general population. #EULAR2021 @RheumNow https://t.co/c45XBLvWrz

• http://ow.ly/Mkmk50F2gey

Data from 5 Nordic registries cohorts in #OP0222: incidence of ILD is 🔽in bDMARD treated PsA vs. RA pts, irrespective of co-medication with MTX. I wonder about evolving dx/seropositivity in pts w/ respect to ILD. #EULAR2021 @RheumNow https://t.co/0qFuXcPhmO https://t.co/gTUUtw80Lv

• http://ow.ly/v46k50F2hGa

Q-DAPSA for Measuring Disease Activity in PsA by Dr. Rachel Tate ( @uptoTate) #EULAR2021 https://t.co/fbi3Kbd2GS https://t.co/afRnle1EJK

• Q-DAPSA for Measuring Disease Activity in PsA | RheumNow

Abstract #POS0296: real-world bDMARD dosing in axSpA and PsA: TNFi are used in approved dosing for most pts, but, non-TNFi-bDMARDs were often used in higher doses, corresponding to increased PsO dosing. #EULAR2021 @RheumNow https://t.co/7Br5UWtHJo https://t.co/UC4UYQpxml

• http://ow.ly/8Jh850F30Dn

Would you take an SLE patient off of HCQ after 15 years of use seeing this data? @rheumnow @Lupusreference @LupusDocLim @Lupusdoc1 @LupusMD

Per Dr. Dorner: women have higher rates of HCQ assc cardiac conduction abnormalities... not sure why... maybe because we prescribe this drug more in women? maybe because they have small volume of distribution than men? maybe women metabolize the medicine differently than men? https://t.co/X9YYJG3Zf0

oh... and this from Ernest Choy and Clive Kelly. Combination therapy with anti-IL-6/anti-fibrotics for RA-ILD? 👀 OP0124 #EULAR2021 @RheumNow https://t.co/oaGjRgkq0x

Nintedanib stalls *progressive fibrosing* RA-ILD (including across CRP and steroid subgroups). Presuming you can tolerate it, maybe there's something we can do for your RA-ILD now, apart from just controlling your arthritis! subanalysis from INBUILD #EULAR2021 @RheumNow https://t.co/hJCd37oRqK

Clever from @DanielAletaha's group, asking: have trial patients really been MTX-optimised pre-enrollment? Placebo arm data from bDMARD trials x2: MTX continuation ACR20 w16: 25% v 12% (MTX works!) Should clinical trials have mandatory run-in periods? OP0127 #EULAR2021 @RheumNow https://t.co/Sx3IKOVKB6

I'm not always a 'What Is New' session kind of guy, but given that it's Maria Cid introducing the always insightful @Sarah_L_Mackie on GCA I'll happily join the other 1012 viewers at #EULAR2021 tuning in! (So far, definitely and elegantly worth it.) @RheumNow https://t.co/kHOus21T1z

After many years without love, RA-ILD therapy seems like it's on the move. MUC5B aside, we've seen abstracts at #EULAR2021 about: - tofacitinib (OP0125) - abatacept (POS0513) - rituximab (POS0645) - nintedanib (below) I discuss it a bit for @RheumNow: https://t.co/nk87kfjacb https://t.co/EjNbA2oLWs

• The Future of Treatment of RA-ILD: Dr. David Liew - YouTube
• https://twitter.com/drdavidliew/status/1400376669504819203

Great to have my @OMERACT irAE group co-chair and friend @MarieKostine remind #EULAR2021 of the EULAR points to consider for irAEs - still relevant in a fast-moving field! available here in full @ARD_BMJ: https://t.co/wFZqKsdDoz in the Oncorheumatology session @RheumNow https://t.co/RuhIlkFRgM

• https://ard.bmj.com/content/80/1/36